MMED News & Events

Sees FY27 adjusted EBITDA margin 16%.

MiniMed (MMED) announced an expanded agreement with Abbott (ABT) to collaborate on commercializing dual glucose-ketone sensors designed to integrate exclusively with MiniMed smart dosing systems. These new dual monitoring sensors are designed to enable early, real-time detection of rising ketones to help prevent diabetic ketoacidosis. The agreement builds on the companies' existing partnership for the Instinct sensor, made by Abbott, and will offer MiniMed users expanded choice across its automated insulin delivery and Smart MDI systems. The sensors will be the same size as the Instinct sensor.

Reports Q4 revenue $837M, consensus $826.52M. "MiniMed delivered a strong finish to our fiscal year, driven by strength in international markets and continued global adoption of the MiniMed 780G system," said MiniMed CEO Que Dallara. "Looking ahead, we're confident that our launches of MiniMed Flex and MiniMed Go will support long-term growth acceleration and value creation."